CHUAN HOLDING (01420) plans to issue approximately 207 million new shares to Mr. Pang Yaojie, raising approximately HKD 15,339.5 million in funds.
(01420) announced that Pang Yaojie will be transferred from a non-executive director to an executive director as of January 1, 2024.
Chuan Holding (01420) announced that Pang Yaojie will be reappointed as an executive director from a non-executive director, effective January 1, 2024. Pang Yaojie will also become the Chairman of the Board of Directors and continue to serve as the Chairman of the Nomination Committee.
On November 17, 2023, the company entered into a subscription agreement with Pang Yaojie. The company plans to issue approximately 207 million new shares to Pang Yaojie, accounting for approximately 16.67% of the enlarged share capital. The subscription price is HKD 0.074 per share, with a total consideration of approximately HKD 15,339,500 in cash.
Related Articles
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a US IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million.
Bank of Canada signals hawkish stance: does not want to act too slowly on rate hikes, oil prices become key risk
US Stock Market Move | Capital Markets Day $23 Billion Target Falls Short of Expectations, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Drops Over 8%
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a US IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million.
Bank of Canada signals hawkish stance: does not want to act too slowly on rate hikes, oil prices become key risk
US Stock Market Move | Capital Markets Day $23 Billion Target Falls Short of Expectations, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Drops Over 8%
RECOMMEND
